RenovoRx, Inc. has announced its financial results for the fiscal year ended December 31, 2025, reporting revenues of $1.1 million from its RenovoCath device, marking a significant increase from $43,000 in 2024. This growth reflects strong initial adoption among physicians and cancer centers. The company has established a solid commercial infrastructure and aims to expand its market presence further in 2026. Additionally, RenovoRx is advancing its Phase III TIGeR-PaC clinical trial, with full enrollment expected by mid-2026 and final data anticipated in 2027. The company has also secured $13 million in cash, positioning it well for future growth and operational milestones.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.